Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause  Chris M.G. Thomas, Ph.D.,

Slides:



Advertisements
Similar presentations
Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States  David B. Seifer, M.D., Valerie.
Advertisements

Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization  Martin D. Keltz,
Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity  Cristian O'Flaherty, Ph.D., Barbara.
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle  Michael W.
Age at menarche: a predictor of diminished ovarian function?
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison 
Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
The normal variabilities of the menstrual cycle
Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.
The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated.
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Rene Ecochard, M. D. , Ph. D. , Thomas Bouchard, M. D. , Rene Leiva, M
Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
A model for predicting age at menopause in white women
Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause  Linlin Cui, M.D., Ph.D., Yingying.
Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles  Angela R. Baerwald, Ph.D.,
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,
Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D
Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women  Ioannis E. Messinis, M.D., Ph.D.,
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.
A comparison of blood spot vs
Triploidy formation after intracytoplasmic sperm injection may be a surrogate marker for implantation  Mitchell P. Rosen, M.D., Shehua Shen, M.D., Anthony.
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Improvements achieved in an oocyte donation program over a 10-year period: sequential increase in implantation and pregnancy rates and decrease in high-order.
Prevalence of premature urinary luteinizing hormone surges in women with regular menstrual cycles and its effect on implantation of frozen-thawed embryos 
Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D
Common 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene affects follicular estradiol synthesis  Stephanie Hecht, Roman Pavlik, Peter.
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study  Li Wei, Ph.D., Thomas MacDonald, M.D.,
René Ecochard, M. D. Ph. D. , Agnes Guillerm, M. D. , René Leiva, M. D
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
Susanna J. Park, M. D. , Laura T. Goldsmith, Ph. D. , Joan H
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Tomer Singer, M. D. , David H. Barad, M. D. , M. S
Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a.
Introduction Fertility and Sterility
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Effect of letrozole at 2. 5 mg or 5
Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.
Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but.
M. Kathleen Clark, Ph. D. , MaryFran R. Sowers, Ph. D
Aaron K. Styer, M. D. , Diane L. Wright, Ph. D. , H. C. L. D. , Anne M
Effectiveness of highly purified human menopausal gonadotropin vs
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Relaxin has a role in establishing a renal response in pregnancy
The menopausal transition
Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.
Women with regular menstrual cycles and a poor response to ovarian hyperstimulation for in vitro fertilization exhibit follicular phase characteristics.
Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome  Yuwen Wu, M.D., Jianhua Zhang,
Follicular fluid of single follicles from women with PCOS contains higher levels of müllerian inhibiting substance  L.T. Ku, S.T. Nakajima, M.E. McClure,
Aline Ketefian, M. D. , Jianfang Hu, Ph. D. , Alfred A. Bartolucci, Ph
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
In vitro sildenafil citrate use as a sperm motility stimulant
Anastrozole single-dose protocol in women with oligo- or anovulatory infertility: results of a randomized phase II dose–response study  Donald Tredway,
Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development 
Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.
Ovarian follicular volume and follicular surface area are better indicators of follicular growth and maturation, respectively, than is follicular diameter 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Presentation transcript:

Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause  Chris M.G. Thomas, Ph.D., Paul N. Span, Ph.D., Jesper M.J. Smeenk, M.D., Ph.D., Rob G.J.M. Hanssen, Ph.D., Didi D.M. Braat, M.D., Ph.D., Fred C.G.J. Sweep, Ph.D.  Fertility and Sterility  Volume 92, Issue 2, Pages 613-619 (August 2009) DOI: 10.1016/j.fertnstert.2008.06.012 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Distribution of FSH and LH glycoforms in seven cyclic women aged 20 to 25 years with FSH <10 IU/L on cycle day 3. Fertility and Sterility 2009 92, 613-619DOI: (10.1016/j.fertnstert.2008.06.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Comparison of the median (25 and 75 percentiles) relative cumulative percent rates of (A) FSH glycoforms at pI >4.3 and (B) LH glycoforms at pI >6.5 for women aged 20 to 25 years versus women aged 40 to 45 years. Black squares with solid lines are from young women (aged 20 to 25 years), open squares with dotted lines are from older (40 to 45 years) women with normal early follicular FSH levels. Fertility and Sterility 2009 92, 613-619DOI: (10.1016/j.fertnstert.2008.06.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Box-plots of relative levels of (A) FSH > pI 4.3 and (B) LH > pI 6.5 in premenopausal women (age 20 to 25 years, 40 to 45 years with normal early follicular FSH [N], 40 to 45 years with higher early follicular FSH [H]) and women with premature ovarian failure (POF) and postmenopausal women (PM). For FSH, a decrease in levels is seen during aging that is already statistically significantly different in older women before FSH rises. Boxes represent mean of levels of all cycle phases of premenopausal women. Fertility and Sterility 2009 92, 613-619DOI: (10.1016/j.fertnstert.2008.06.012) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions